Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A carries a market capitalization of 71.11B, placing it among publicly traded companies globally. Its enterprise value stands at 109.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A's next confirmed earnings release is scheduled for October 27, 2026.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A has 2.67B shares outstanding.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 20.55. The price-to-sales ratio is 1.68, and the price-to-book ratio stands at 1.45.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A trades at an EV/EBITDA multiple of 20.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 109.88B versus a market cap of 71.11B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.09, indicating elevated leverage, while an interest coverage ratio of 4.40 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A posted a return on equity (ROE) of 7.09, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.84, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.49, useful for judging operating efficiency across full business cycles. The company generates approximately 1.03M in revenue per employee across its workforce of 40,580.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.12 indicates how many times Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A recorded 978.99M in income tax expense. That works out to an effective tax rate of 18.30, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.35B, leaving 3.42B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A's stock has declined approximately 21.36% over the past 52 weeks. The 50-day moving average sits at 23.07, while the 200-day moving average is 24.55.

Over the twelve months ended March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A generated 41.86B in revenue and converted that into 3.42B in net income, yielding earnings per share of 1.66. EBITDA reached 5.46B, while operating income came in at 3.25B.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A holds 15.29B in cash and equivalents against 39.53B in total debt, resulting in a net debt position of 15.87B. Total book value stands at 49.15B, with working capital of -2.62B providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A posted a gross margin of 50.39, reflecting its pricing power and cost economics. The operating margin of 7.76 and net profit margin of 8.17 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A paid dividends of 0.41 per share. The dividend payout ratio of 20.21 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A shareholders.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A's most recent stock split took place on July 26, 2010 with a 2:3 split ratio.

As of March 31, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A has an Altman Z-Score of 1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.